Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1623 1648 1671 1672
This examiner grants 58% of resolved cases
Nicole Erin Kinsey White is a patent examiner in Tech Center 1600, specifically working within Art Unit 1623. This examiner has overseen 876 resolved cases, which provides a substantial statistical foundation for analyzing their historical prosecution patterns. These 876 resolved cases encompass all applications that have reached a final decision under their review in Art Unit 1623 and Tech Center 1600.
The data reveals an allowance rate of 58.1 percent, which reflects the proportion of applications that are successfully granted. The median days to allowance for these cases is 1187. This duration of 1187 days represents the typical timeline for reaching a favorable outcome. The 58.1 percent allowance rate serves as a primary benchmark for applicants when planning their prosecution strategy.
The interview lift for this examiner is 16.4 percent. This 16.4 percent lift indicates that conducting an interview is associated with an increase in the probability of allowance compared to the baseline rate of 58.1 percent. Given the median days to allowance of 1187, the 16.4 percent interview lift suggests that direct communication with the examiner is a valuable tool for improving the likelihood of a successful grant.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18748403 | Methods and Materials for Using Measles Viruses | Non-Final OA | Mayo Foundation for Medical Education and Research |
| 18572427 | DETECTION OF A TARGET VIRUS VIA SURFACE ENHANCED RAMAN SPECTROSCOPY (SERS) USING A PEPTIDE-MODIFIED NANOSTRUCTURED METAL | Non-Final OA | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL |
| 18606343 | METHODS OF BOOSTING AN IMMUNE RESPONSE AGAINST HIV USING COMMENSAL MICROBE ANTIGENS | Non-Final OA | VANDERBILT UNIVERSITY |
| 17922662 | COMPOSITIONS AND METHODS FOR CORONAVIRUS DETECTION | Non-Final OA | The Johns Hopkins University |
| 18286855 | DETECTION OF SARS-COV-2 VARIANT | Non-Final OA | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM |
| 18500064 | Dynamic Clinical Assay Pipeline for Detecting a Virus | Non-Final OA | Laboratory Corporation of America Holdings |
| 18286732 | FUNCTIONALIZED BIOLOGICAL MEMBRANES WITH MODIFYING PROTEIN MOLECULES, AND METHODS OF MAKING AND USES THEREOF | Non-Final OA | McMaster University |
| 17923118 | MOLECULAR TRANSPORT FOR VIRAL AGENTS | Final Rejection | McMaster University |
| 18711338 | METHODS OF PREVENTING, TREATING, OR REDUCING THE SEVERITY OF CORONAVIRUS DISEASE 2019 (COVID-19) | Non-Final OA | CITY OF HOPE |
| 17924784 | RSV VACCINE BEARING ONE OR MORE P GENE MUTATIONS | Final Rejection | The United States of America,as represented by the Secretary,Department of Health and Human Services |
| 18486708 | Vaccines For Recurrent Respiratory Papillomatosis And Methods of Using the Same | Non-Final OA | Inovio Pharmaceuticals, Inc. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy